ESC Premium Access

Antiplatelet is associated with the higher risk of periprocedural complication of catheter ablation for atrial fibrillation

Congress Presentation

About the speaker

Doctor Takahiro Iseda

Japan Red Cross Society Wakayama Medical Center, Wakayama (Japan)
0 follower

24 more presentations in this session

Patients with atrial fibrillation treated with apixaban are less likely to discontinue study drug when compared with warfarin: insights from the ARISTOTLE trial

Speaker: Professor D. Xavier (Bangalore, IN)


Incidence of intracranial hemorrhage in the years 2013-15 in patients with atrial fibrillation in anticoagulant therapy: preliminary analysis of data from Ravenna registers

Speaker: Doctor C. Gatti (Ravenna, IT)


High SAMe-TT2R2 score, labile INR and major adverse outcomes in a real life cohort of anticoagulated patients with non-valvular atrial fibrillation

Speaker: Doctor D. Iglesias (Santiago de Compostela, ES)


CHA2DS2-Vasc score, as well as age and body mass index as the main risk factors of brain lesions in asymptomatic patients with paroxysmal non-valvular atrial fibrillation

Speaker: Doctor J. Wieczorek (Katowice, PL)


Novel oral anticoagulants in a real-world cohort of patients undergoing catheter ablation of atrial fibrillation

Speaker: Doctor A. Parwani (Berlin, DE)


Access the full session

Poster session 3 - Anticoagulation in atrial fibrillation III

Speakers: Doctor T. Iseda, Professor D. Xavier, Doctor C. Gatti, Doctor D. Iglesias, Doctor J. Wieczorek...

About the event


ESC Congress 2016

27 August - 31 August 2016

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb